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There is growing consensus that multigene prognostic tests provide useful complementary information to tumor
size and grade in estrogen receptor (ER)-positive breast cancers. The tests primarily rely on quantification of ER and
proliferation-related genes and combine these into multivariate prediction models. Since ER-negative cancers tend
to have higher proliferation rates, the prognostic value of current multigene tests in these cancers is limited.
First-generation prognostic signatures (Oncotype DX, MammaPrint, Genomic Grade Index) are substantially more
accurate to predict recurrence within the first 5 years than in later years. This has become a limitation with the
availability of effective extended adjuvant endocrine therapies. Newer tests (Prosigna, EndoPredict, Breast Cancer
Index) appear to possess better prognostic value for late recurrences while also remaining predictive of early
relapse. Some clinical prediction problems are more difficult to solve than others: there are no clinically useful
prognostic signatures for ER-negative cancers, and drug-specific treatment response predictors also remain elusive.
Emerging areas of research involve the development of immune gene signatures that carry modest but significant
prognostic value independent of proliferation and ER status and represent candidate predictive markers for
immune-targeted therapies. Overall metrics of tumor heterogeneity and genome integrity (for example, homologue
recombination deficiency score) are emerging as potential new predictive markers for platinum agents. The recent
expansion of high-throughput technology platforms including low-cost sequencing of circulating and tumor-derived
DNA and RNA and rapid reliable quantification of microRNA offers new opportunities to build extended prediction
models across multiplatform data.Introduction
Oncologists involved in the clinical management of
breast cancer have to consider several different clinical
and molecular characteristics of the tumor, in addition
to patient preferences and comorbidities, when formu-
lating therapeutic recommendations for early stage,
potentially curable cancers. Some clinical–pathologic
characteristics including tumor size, nodal status, and lym-
phovascular invasion are risk factors associated with prog-
nosis (that is, the probability of disease-free survival with
surgery alone in the absence of any systemic adjuvant
therapy), while others such as histologic grade, estrogen
receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) status, and
proliferation rate are associated with both prognosis and
sensitivity to treatment modalities (Figure 1) [1]. Low* Correspondence: lajos.pusztai@yale.edu
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status are each independently associated with better prog-
nosis in patients treated with surgery alone (or with sur-
gery and adjuvant endocrine therapy if ER-positive) and
also predict lesser sensitivity to chemotherapy. On the
contrary, high histologic grade and high proliferation rate
are associated with worse prognosis but at the same time
also predict for higher chemotherapy sensitivity, which is
apparent from the higher rates of pathologic complete re-
sponse to neoadjuvant chemotherapy and higher relative
benefit from adjuvant chemotherapy among cancers with
these molecular features.
There are a number of subtleties to predictive and
prognostic markers that clinicians and investigators need
to be aware of. The prognostic or predictive strength of
different features is variable. For example, nodal status is
a more powerful prognostic predictor than HER2 status
[2]. The same marker can have different prognostic or
predictive values in different molecular subtypes of breast
cancer. For example, high proliferation rate measured by. The licensee has exclusive rights to distribute this article, in any medium, for 6
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Figure 1 Prognostic and predictive relationship between multigene signatures and prognostic and predictive features in breast cancer.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LVI, lymphovascular invasion; PR, progesterone receptor.
Győrffy et al. Breast Cancer Research  (2015) 17:11 Page 2 of 7Ki67 expression and high grade have greater prognostic
value and are more predictive of chemotherapy response
in ER-positive cancers than in triple-negative breast can-
cers (TNBCs) (ER-, PR- and HER2-negative). All currently
known prognostic and predictive features are only partially
independent from one another. For example, ER-negative
cancers tend to have high grade and high proliferation
rate. Larger cancers are more likely to be node-positive.
Finally, the different markers represent different types of
distributions and are quantified with variable accuracy.
Age, tumor size and Ki67 expression represent continuous
variables that approximate a normal distribution. The
ER and PR expression by immunohistochemistry or by
mRNA levels are continuous variables with a bimodal
distribution. Histologic grade and nodal status are or-
dinal variables, whereas HER2 gene amplification results
are used as a binary variable. The quantification of ER,
PR and HER are increasingly standardized and between-
laboratory reproducibility has improved substantially
over the past few years. However, histologic grade and
Ki67 immunohistochemistry has only modest between-
laboratory concordance. Tumor size measurements in
many pathology laboratories tend to cluster around whole
numbers, suggesting rounding to the nearest number.
When multiple, partially independent factors mea-
sured with variable accuracy on different scales are asso-
ciated with an outcome, the most accurate predictions
can only be achieved by multivariate prediction models.
This justifies the efforts to build multivariate prognostic
models such as AdjuvantOnline (Adjuvant! Inc., San
Antonio, TX, USA) and multigene predictors. Empiric-
ally developed multigene prognostic predictors have the
theoretical advantages of optimal use of information
from continuous variables, proper weighting of each
variable, and robustness through redundancy by captur-
ing similar information from multiple genes (that is, ER
activity or proliferation are assessed through a cluster of
genes rather than ER or Ki67 alone) and the potential toidentify and incorporate new molecular variables into
the model. However, they also have limitations; most im-
portantly, some powerful anatomical–pathologic prog-
nostic risk factors such as tumor size and nodal status
have no consistent molecular imprint and therefore
these variables are not captured by empirically devel-
oped gene signatures. Also, some of the theoretical ad-
vantages have not fully materialized in practice. No
robust, new, prognostic genes have been identified that
are unrelated to proliferation or ER signaling, and when
novel genes are included in multigene tests their contri-
bution to the outcome prediction is modest. To what ex-
tent quantification of ER-related or proliferation-related
metagenes provides robustness or increased accuracy
over reliably quantifying ER and Ki67 also remains uncer-
tain. Despite these limitations, there is growing consensus
that multigene prognostic gene signatures provide stan-
dardized, complimentary information to routine patho-
logical variables including tumor size, nodal status and
histologic grade. Multigene prognostic assays are now en-
dorsed by the American Society of Clinical Oncology, St.
Gallen and National Comprehensive Cancer Network
guidelines as information that could assist therapeutic
decision-making in ER-positive cancers. The following
sections are brief reviews of clinically available assays.
IHC4 assay
The IHC4 assay is based on a multivariate model that
uses semiquantitative information from immunohisto-
chemical assessment of ER, PR, HER2 and Ki67. The
assay is performed on formalin-fixed, paraffin-embedded
(FFPE) tumor biopsy specimens and a risk score for re-
currence is calculated by an algorithm [3].
While the IHC4 test is elegant in its simplicity and has
similar performance characteristics to the more complex
and expensive commercial tests, it uses information
from ER, PR and Ki67 differently to how these markers
are currently interpreted in routine practice. Physicians
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ER-positive vs. ER-negative, Ki67 low vs. Ki67 high, and
so forth) and create distinct groups (with four binary
markers, 16 different marker groups are possible); in
contrast, IHC4 uses a mathematical formula that weighs
the semiquantitative expression values and combines
these into a single risk score. The mathematical equation
behind the IHC4 score is public; however, in the absence
of standardized quantification of each of the four vari-
ables that would match the IHC assay sensitivity and
the dynamic ranges used in the seminal paper, applying
the formula to local pathology results could be highly
misleading.
MammaPrint score
MammaPrint (Agilent, Amsterdam, the Netherlands) is
a microarray-based prognostic score performed by a
central laboratory that was approved by the US Food
and Drug Administration and by regulators in the
European Union as an adjunct prognostic assay for
breast cancer patients younger than 61 years of age
with stage I/II, lymph node-negative or one to three
lymph node-positive disease [4].
MammaPrint measures the mRNA expression of 70
genes and stratifies patients into low-risk or high-risk
prognostic groups [5]. The prognostic risk discrimin-
ation is good among ER-positive cancers but almost all
ER-negative cancers are classified as high risk, which
limits the score’s clinical value in this disease subset.
Retrospective analysis of a large multicenter patient
cohort (n = 541) suggested that only the high-risk ER-
positive patients benefited from adjuvant chemotherapy
[6,7]. The original assay required fresh-frozen material,
which limited its clinical uptake, particularly in the
United States. More recent versions of the test can use
FFPE tissues [8].
A large prospective trial (MINDACT) has tested the
clinical utility of MammaPrint and accrued 6,600 pa-
tients between 2006 and 2011; results from this trial are
expected in 2015. This study has also created a unique
tissue and gene expression data resource that will allow
the development and testing of the next generation of
prognostic gene signatures.
PAM50/risk of recurrence/Prosigna kit
In September 2013 the US Food and Drug Administra-
tion approved a second prognostic signature (Prosigna;
Nanostring Technologies, Seattle, WA, USA) that also
received clearance in the European Union. Prosigna is a
diagnostic kit that uses Nanostring technology to quan-
tify mRNA expression of 50 genes used in the PAM50
molecular classification algorithm and a series of house-
keeping genes (that are used for normalization) as well
as positive and negative controls in FFPE tissues tocompute a risk of recurrence score. The risk of recur-
rence score reflects but does not explicitly report the in-
trinsic breast cancer subtype of the case [9,10].
The assay is approved to estimate distant recurrence-
free survival for stage I/II (including one to three posi-
tive nodes), ER-positive breast cancer in postmenopausal
women treated with adjuvant endocrine therapy. An ap-
pealing aspect of this test is that it can be performed by
local pathology laboratories although it requires an ex-
pensive piece of equipment, the Nanostring nCounter
Dx Analysis System (Nanostring Technologies).Oncotype DX assay
Currently, Oncotype DX (Genomic Health, Redwood
City, CA, USA) is the most widely used prognostic assay
for ER-positive cancers in the United States. This assay
utilizes expression measurements from 16 cancer-related
genes and five housekeeping genes to compute a recur-
rence score from 0 to 100, which can be categorized into
low-risk (score <18), intermediate-risk (score 18 to 30)
or high-risk (score ≥31) groups [11]. Measurement is
performed on FFPE specimens in a central laboratory.
Several studies on archived tissues from randomized
adjuvant chemotherapy trials demonstrated benefit from
adjuvant chemotherapy primarily in patients with high
recurrence score. A larger, prospective, randomized clin-
ical trial (TAILORx) has tested the utility of adjuvant
chemotherapy in node-negative woman with intermedi-
ate risk for recurrence by Oncotype DX (that is, recur-
rence score 11 to 25); accrual has been completed and
the first results are expected in 2017.
Recently, a multivariate model has been developed that
takes information from the Nottingham grade, ER and
PR immunohistochemistry results, HER2 status, tumor
size and Ki67 expression to predict the recurrence score
category [12]. The equation has been tested on large
datasets, and through the combination of these routinely
available variables all non-intermediate recurrence-score
risk categories could be predicted with high accuracy
(96 to 100%). This recurrence score category predictor is
available online [13].Genomic grade index
The Genomic Grade Index (MapQuant Dx, Ipsogen,
France) is a microarray-based assay that measures the
expression of 97 genes to assign a molecular grade. The
assay was developed by comparing gene expression pro-
files of grade I and grade III tumors [14]. A smaller six-
gene version has also been developed that uses RT-PCR
technology and can be readily applied to FFPE samples
[15]. The test can reclassify histologically intermediate-
grade ER-positive cancers into high or low molecular
grade with significantly different prognosis.
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The Breast Cancer Index (BioTheranostics, San Diego,
CA, USA) is an RT-PCR-based assay that can be applied
to FFPE tissues and is performed by a central laboratory
to predict the risk of distant recurrence in ER-positive,
lymph node-negative breast cancers. This assay includes
two independent biomarkers, the HOXB13:IL17BR ratio
and a five-gene molecular grade index that primarily
consists of proliferation-related genes [16,17]. The two
signatures together comprise the Breast Cancer Index
score.
A strength of the Breast Cancer Index is that it can be
used to predict risk of both early (within 5 years) and
late (>5 years) distant recurrences and also reports the
likelihood of benefit from extended endocrine therapy.
The Breast Cancer Index outperformed the IHC4 or
Oncotype DX assays in predicting late recurrence when
all three tests were applied to the same cases with long-
term follow-up [18]. The Breast Cancer Index identifies
a substantial minority of patients (35 to 45%) who are at
high risk for late recurrences, and these patients may be
considered optimal candidates for extended adjuvant
therapy.
EndoPredict assay
The EndoPredict test (Sividon Diagnostics GmbH, Koln,
Germany), also an RT-PCR-based assay, measures the
expression of eight cancer genes and three housekeeping
control genes to stratify patients with ER-positive cancer
into a low or a high risk of recurrence if treated with
adjuvant endocrine therapy alone [19]. The assay is
marketed in Europe as a diagnostic kit that can be per-
formed by local laboratories. In addition, the EndoPredict
score has also been combined with nodal status and tumor
size to compute a comprehensive risk score termed EPclin.
The performance of EPclin was validated in two ran-
domized phase III trials [20]. EndoPredict also identifies
ER-positive patients who are at risk for late recurrence [21].
Concordance of risk assignment by different tests
The advent of multiple different tests available in the
clinic for the same purpose inevitably raises the question
of concordance in risk assignment when more than one
of the tests are applied to the same specimen. Compara-
tive studies indicate that discordant risk prediction
frequently occurs when different prognostic assays are
applied to the same case. When six genomic signatures,
including PAM50/risk of recurrence, MammaPrint, and
Oncotype DX, were tested on the same patient cohort,
each test had significant prognostic value but individual
risk assignments were often discordant [22].
In another study, when molecular classification with
PAM50 was compared with Oncotype DX risk categor-
ies among the luminal A cancers by PAM50, 70% werelow risk and the remainder were intermediate risk by
Oncotype DX. Among luminal B cancers, 33% were
high risk and 48% were intermediate risk by Oncotype
DX. Ninety percent of high-risk cases by Oncotype DX
were classified as luminal B and 83% of low-risk cases
were luminal A. Importantly, one-half of intermediate
recurrence score cancers were recategorized as low-risk
luminal A cancers by PAM50 [23].
Another analysis of six different prognostic signatures
applied to the same cases also showed only moderate
agreement between prediction results in pairwise com-
parisons; Cohen’s kappa ranged from 0.236 to 0.701 [24].
Similarly high discordance rates for Oncotype DX and
MammaPrint risk categories were reported; more than
30% of MammaPrint high-risk cases were reclassified as
low risk by Oncotype DX [24].
Prediction of chemotherapy benefit
It is possible to predict general chemotherapy sensitivity
by capturing proliferation-related markers, particularly
among ER-positive cancers. The higher chemotherapy
sensitivity is reflected by higher pathologic complete re-
sponse rates to a broad range of preoperative regimens
and also by the greater benefit from adjuvant chemo-
therapy in general. Biomarker subset analysis of two sep-
arate studies (NSABP B-20 and SWOG 8814) has shown
that adjuvant chemotherapy improved disease-free sur-
vival only in ER-positive cancers with high recurrence
score, while benefit was not seen, or was minimal, in low-
risk and intermediate-risk patients, respectively [14,25].
However, the quest for drug-specific or treatment
regimen-specific predictive markers remains elusive. The
most plausible explanation for the limited predictive
values of proposed molecular predictors for individual
drugs is the multifactorial nature of chemotherapy sensi-
tivity. Empirical development of predictive models as-
sumes there are shared molecular features that are
common to all, or most, sensitive or resistant cases. If
such informative features exist, they can easily be identi-
fied through statistical methods and combined into a
multivariate model to predict response in future cases.
However, it appears that there are very few molecular
features which are associated with individual drug re-
sponse and are shared across many patients [26]. Data
from gene expression profiling as well as from next-
generation sequencing indicate that each cancer contains
a variable number and unique assortment of genomic
abnormalities. This suggests that each cancer may be
sensitive or resistant to a particular treatment in its own
unique way. In other words, a particular biological path-
way that contributes to drug sensitivity can be affected
through many different mechanisms, including muta-
tions, amplifications, deletions, epigenetic regulation,
microRNA, and so forth, at many different levels along
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cellular and genomic heterogeneity further increases
complexity.
A corollary of tumor heterogeneity is that some
genome-wide metric of tumor heterogeneity or genomic
disturbance may function as biomarkers. Indeed, one of
the promising, novel, drug class-specific predictors in-
cludes quantifying the effects of homologous DNA re-
combination deficiency on the genome, regardless of its
molecular etiology, by simultaneously assessing whole
genome loss of heterozygosity, telomeric allelic imbal-
ance and large-scale state transitions. These three
metrics can be combined into a single homologous
recombination deficiency score (HRD assay; Myriad
Genomic, Salt Lake City, UT, USA). A high homologous
recombination deficiency score indicates defective hom-
ologous recombination repair that renders cells vulner-
able to accumulation of DNA damage after exposure to
DNA crosslinking drugs, particularly platinum agents.
Several retrospective correlative studies showed a good
correlation between the homologous recombination de-
ficiency score and the response to platinum therapy in
breast cancer and ovarian cancer [27,28]. The assay is
performed on DNA extracted from FFPE tissue sections
and uses single nucleotide polymorphism arrays and
high-throughput sequencing. Prospective trials to assess
the clinical value of the assay for patient selection to
platinum therapy are underway.
Conclusions
Multigene signatures introduced an important concept
into prognostic marker research: the need for multivari-
ate prediction models. This represents a conceptual ad-
vance over arbitrary groupings based on combinations of
single prognostic variables such as clinical tumor staging
using the tumor, node, metastasis classification. A sec-
ond important conceptual contribution was shifting the
emphasis from pure, primary prognostic prediction (that
is, who has excellent prognosis with surgery alone) to
secondary risk stratification, recognizing that essentially
all ER-positive breast cancer cases are offered adjuvant
endocrine therapy and therefore the relevant clinical
question is who remains at high risk for recurrence des-
pite endocrine therapy and is therefore a potential candi-
date for adjuvant chemotherapy.
The first generation of multigene prognostic predictors
was developed empirically by comparing gene expression
data from patients who did or did not experience recur-
rence. These attempts identified ER-related genes and
proliferation markers as the two most powerful molecu-
lar processes associated with outcome. Since ER has a
very broad transcriptional footprint and cell proliferation
requires the coordinated expression of hundreds of
genes, a very large number of nominally different butequally good prognostic models can be built from the
same dataset. This redundancy in the prognostic variable
space for ER-positive cancers explains the existence of
many different prognostic gene signatures in the com-
mercial space and in academic research laboratories.
Since each model uses different gene sets and was opti-
mized in distinct training sets, when multiple models are
applied to the same independent validation set they all
identify low-risk and high-risk cohorts but also tend to
show substantial discordance (20 to 30%) in risk assign-
ment at the individual case level. Somewhat surprisingly,
no molecular markers emerged that are associated with
tumor size and nodal status, which are the two most im-
portant anatomical prognostic variables. This also im-
plies that prognostic information embedded in size and
nodal status is not captured in empirically developed
prognostic gene signatures. For this reason, multivariate
clinical prognostic models such as AdjuvantOnline and
molecular models tend to result in highly discordant risk
assignment at the individual case level.
From these basic performance characteristics emerges
the current clinical utility of genomic prognostic assays.
All major practice guidelines endorse molecular assays
to aid prognostic risk prediction in ER-positive, T1–T2
breast cancers with zero to three positive nodes. While
the molecular assays retain their prognostic discriminat-
ing value regardless of anatomical risk factors, the final
risk of recurrence is determined by both molecular and
anatomical features because tumor size and nodal status
represent independent prognostic variables [29]. The in-
verse relationship between proliferation and prognosis
and chemotherapy sensitivity in ER-positive cancers con-
veniently allows the identification of patients who are
higher risk for recurrence and at the same time have
higher sensitivity to chemotherapy. The flip side of this
association is that patients with molecularly low-risk
cancers with anatomically high-risk features (for ex-
ample, multiple positive lymph nodes) may not derive
significant benefit from adjuvant chemotherapy – this
concept is currently being tested in a prospective ran-
domized clinical trial (SWOG 1007). Genomic prognos-
tic tests are also increasingly used as patient selection
tools for clinical trials and to define clinically relevant
patient populations for drug development (Figure 2).
Important new areas of research have also emerged.
One area where the performance of existing tests could
be improved is more accurate prediction of late recur-
rences in ER-positive cancer. The clinical importance of
this is underscored by the recognition that around 50%
of all recurrences in ER-positive cancers develop after
5 years and the rate of late recurrences can be reduced
by extended adjuvant endocrine therapy. A series of new
prognostic tests are emerging (Breast Cancer Index,
EndoPredict, Prosigna) that address this diagnostic niche.
Figure 2 Conceptual framework for risk stratification and currently available prognostic and predictive tools. Aces, Adjuvant chemotherapy
and endocrine therapy sensitivity signature [29]; BCI, Breast Cancer Index; ER, estrogen receptor; GGI, Genomic Grade Index; HER2, human epidermal
growth factor receptor 2.
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the currently high-risk ER-positive cancer cases (high re-
currence score or luminal B molecular class) that are no
longer at high risk after receiving adjuvant chemotherapy
[30]. This represents the next logical extension of residual
risk prediction. The clinical importance of a postche-
motherapy and postendocrine therapy, tertiary risk pre-
dictor is that it could define the ER-positive patient
population to whom new drug development should be
targeted.
One of the most puzzling observations in breast can-
cer biomarker research has been the difficulty to identify
clinically useful molecular prognostic markers for TNBC.
While it is possible to define better and worse outcome
groups among these cancers by capturing information
about immune cell and inflammatory infiltration, the prac-
tical value of these observations is limited because even
“good-risk” patients have close to 20% risk of distant re-
currence in the absence of systemic adjuvant therapy [31].
Considering the clinical context in TNBC, which involves
choosing between observation versus adjuvant chemother-
apy, and the lack of data to support that adjuvant chemo-
therapy could not improve the outcome of the “good-risk”
patients further, a 20% risk of recurrence is too high for
most patients and physicians. One might propose that
searching for pure primary prognostic markers in TNBC
is likely to be futile. On the contrary, developing residual
risk predictors that identify TNBC with low risk ofrecurrence after completing adjuvant chemotherapy could
be helpful [32]. However, this information can be readily
obtained by administering the intended adjuvant chemo-
therapy preoperatively. Pathologic complete response in
this disease subset identifies patients who have excellent
long-term survival with a given chemotherapy [33]. The
most pressing clinical need for TNBC might be to develop
more effective new drugs.
Finally, the advent of several new high-throughput
technology platforms including RNA sequencing, micro-
RNA profiling and analysis of free circulating DNA al-
lows substantial broadening of the variable space for
multivariate model development. Research groups are
exploring these new opportunities to build extended pre-
diction models across multiplatform data.
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